AUM $154.6MER 0.50%NAV $52.84Holdings 103Inception Dec 2014
Price Chart
Key Statistics
Previous Close
$52.09Day Range
$52.19$53.60
52-Week Range
$29.94$57.67
Avg Volume
24.8KDividend Yield
2.29%Expense Ratio
0.50%AUM
$154.6MShares Outstanding
3.0METF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 82.46% |
| Ireland | 4.89% |
| Netherlands | 3.85% |
| Canada | 2.95% |
| Switzerland | 1.32% |
| Belgium | 1.27% |
| China | 1.27% |
| United Kingdom | 1.13% |
| Germany | 0.90% |
Fund Information
- Issuer
- ALPS Funds
- Category
- Healthcare
- Types
- Healthcare
- Inception Date
- Dec 30, 2014
- Exchange
- NYSE_ARCA
- Description
- The ALPS Medical Breakthroughs ETF (SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (PMBI).
Similar ETFs
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund issued by ALPS Funds that launched on Dec 30, 2014. It currently manages $154.6M in assets under management. The fund charges an expense ratio of 0.50%. The fund holds 103 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 35.6% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | ALKS | Alkermes PLC | 5.02% | 170,377 | $7.7M |
| 2 | KYMR | Kymera Therapeutics Inc. | 4.54% | 83,470 | $6.9M |
| 3 | SYRE | Spyre Therapeutics Inc. | 4.25% | 80,298 | $6.5M |
| 4 | MIRM | Mirum Pharmaceuticals Inc. | 4.02% | 61,690 | $6.1M |
| 5 | APGE | Apogee Therapeutics Inc. | 3.36% | 57,252 | $5.1M |
| 6 | CGON | CG oncology Inc. | 3.26% | 86,325 | $5.0M |
| 7 | TVTX | Travere Therapeutics Inc. | 3.02% | 94,303 | $4.6M |
| 8 | XENE | Xenon Pharmaceuticals Inc. | 2.91% | 85,051 | $4.4M |
| 9 | CELC | Celcuity Inc. | 2.77% | 47,306 | $4.2M |
| 10 | ACAD | ACADIA Pharmaceuticals Inc. | 2.44% | 174,308 | $3.7M |
| 11 | EWTX | Edgewise Therapeutics Inc. | 2.44% | 109,668 | $3.7M |
| 12 | CRNX | Crinetics Pharmaceuticals Inc. | 2.35% | 107,048 | $3.6M |
| 13 | NAMS | Newamsterdam Pharma Co. NV | 2.33% | 117,548 | $3.6M |
| 14 | DNTH | Dianthus Therapeutics Inc. | 2.28% | 45,464 | $3.5M |
| 15 | DNLI | Denali Therapeutics Inc. | 2.23% | 162,136 | $3.4M |
Page 1 of 3
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | +1.70% | |
| 1W | +4.81% | |
| 1M | -1.18% | |
| 3M | +4.08% | |
| 6M | +4.65% | |
| YTD | +5.18% | |
| 1Y | +71.44% | |
| 3Y | +58.77% | |
| 5Y | +7.61% |
Moving Averages
20-Day MA
$52.30
Above 20-Day MA50-Day MA
$53.92
Below 50-Day MA200-Day MA
$48.24
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$57.67
Current Price
$52.98
52-Week Low
$29.94
$29.94$57.67
Current Yield
2.29%
Annual Dividend
$2.0445
Frequency
1x/year
Last Ex-Date
Dec 19, 2024
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 19, 2024 | $1.1735 | Dec 26, 2024 |
| Dec 21, 2023 | $0.0711 | Dec 27, 2023 |
| Dec 19, 2019 | $0.0158 | Dec 27, 2019 |
| Dec 20, 2018 | $0.7841 | Dec 27, 2018 |
| Dec 21, 2017 | $0.5795 | Dec 28, 2017 |
Dividend Payments Over Time
Category Comparison
| Metric | SBIO | Healthcare(176 ETFs) | Healthcare(24 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.50% | 0.61% | 0.48% |
| AUM | $154.6M | $910.0M | $676.9M |
| Dividend Yield | 2.29% | 3.35% | 1.61% |
| Avg Volume | 24.8K | 275.1K | 127.8K |
| Holdings | 103 | 99 | 76 |
| Performance | |||
| 1-Month Return | -5.31% | +1.77% | +1.22% |
| 6-Month Return | +3.84% | +3.26% | +2.52% |
| YTD Return | +3.01% | +3.61% | +2.71% |
| 1-Year Return | +69.16% | +24.59% | +18.78% |
Compare with Another ETF
Search for an ETF to compare with SBIO:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.